Multi-author Review Thrombospondins: from structure to therapeutics Coordinator: D. D. Roberts Cell. Mol. Life Sci. 65 (2008) 669 â 671 1420-682X/08/050669-3 DOI 10.1007/s00018-007-7483-2 Birkhäuser Verlag, Basel, 2008 Cellular and Molecular Life Sciences D. D. Roberts Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-1500 (USA), Fax: + 1 301 402 0043, e-mail: droberts@helix.nih.gov Online First 12 January 2008 Keywords. Extracellular matrix, bone development, angiogenesis, hemostasis, blood flow, inherited disorders, cancer. Introduction (Part of a Multi-author Review) Following its discovery in 1971 as a major protein released by activated platelets, thrombospondin-1 (TSP1) spent several decades in search of a physiological function. Early studies indicated that it modulates platelet aggregation, but when TSP1 null mice were first described in 1998, no defect in platelet function was apparent [1]. Furthermore, the null mice appeared relatively normal, with minor defects in skeletal development, fertility, and lung homeostasis. Nevertheless, TSP1 is expressed in various tissues during embryonic development with a complex choreography, and most cells in culture express and secrete TSP1 in response to specific growth factors. In healthy adults, TSP1 is expressed at low levels in most tissues apart from megakaryocytes and platelets,
/lp/springer-journals/thrombospondins-from-structure-to-therapeutics-T8NpKJTcX4